02-Apr-2012 By Gareth Macdonald
Affymetrix will distribute a mircoarray developed by Almac for personalised medicine development applications under an exclusive global distribution deal.
22-Mar-2012 By Nick Taylor
AMRI is to end operations at its discovery and chemistry services facility in Hungary by the end of next week.
update
15-Mar-2012 By Gareth Macdonald
Two major ferry companies have decided to stop shipping animals used in preclinical drug development to the UK, prompting concerns about the future of the country’s research sector.
15-Mar-2012 By Nick Taylor
Growth in demand for toxicology services will be weak for the foreseeable future as the sector has “structurally changed”, analysts said after SOT.
14-Mar-2012 By Gareth Macdonald
UK drug major AstraZeneca has contracted BioFocus and Argenta to provide it with discovery services just weeks cutting its internal R&D capacity.
13-Mar-2012 By Nick Taylor
WuXi expects its GLP toxicology unit to turn profitable this year and it, like ShangPharma, is pinning its growth hopes on new services.
13-Mar-2012 By Gareth Macdonald
Preclinical CRO CiToxLAB has added inhalation testing capacity, citing growing demand from Pharmas and chemicals firms as key driver for the investment.
UPDATE
06-Mar-2012 By Natalie Morrison
Horizon Discovery has launched a new website to provide technical support to researchers using its rAAV-mediated genome editing tech.
05-Mar-2012 By Gareth Macdonald
Bioanalytical Systems (BASi) will restructure its laboratory operations in a bid to cut costs and maintain an operating profit.
28-Feb-2012 By Nick Taylor
A Chinese company that offers drug development services using a network of 99 third-party vendors has filed an $80m IPO.
27-Feb-2012 By Natalie Morrison
TIBCO and ChemAxon have combined forces over their chemical analysis software in a bid to “speed up and refine” the compound selection process.
Ex-AstraZeneca staff open CRO near to closed UK R&D site
21-Feb-2012
Former AstraZeneca employees have created a niche drug discovery CRO near to the UK site the big pharma firm closed last year.
21-Feb-2012 By Nick Taylor
Researchers have said the outlook of drug discovery in India is “poor” after analysing intellectual property generated by CROs.
15-Feb-2012 By Nick Taylor
GLP toxicology capacity is filling up after repeated cuts but it will be years until more space is needed, the CEO of Charles River said.
13-Feb-2012 By Nick Taylor
BASi is looking at staffing levels to “sharply” cut costs after posting first quarter results a shareholder called “pitiful”.
08-Feb-2012 By Natalie Morrison
BASi says its new sampling tech will allow for quicker, cheaper and more accurate animal testing through its “low-stress” lab.
06-Feb-2012 By Nick Taylor
Thermo Fisher Scientific is predicting strong growth for its laboratory services unit as clients turn to outsourcing to boost productivity.
30-Jan-2012 By Nick Taylor
Covance could cut early development capacity if the unit posts flat sales in the coming fiscal year, its CEO said.
26-Jan-2012 By Gareth Macdonald
Jubilant Life Sciences has bought US drugmaker Eli Lilly’s stake in the early-stage development focused JV the firms set up in 2008.
26-Jan-2012 By Nick Taylor
Covance is accelerating IT investment faster and for longer than expected, resulting in 2012 guidance that met analysts’ “worst-case fears”.
24-Jan-2012 By Nick Taylor
Preclinical CROs begin reporting full year results this week, with talk of takeovers and toxicology high on agendas.
18-Jan-2012 By Natalie Morrison
VivoPharm says its new agreement with primary patient-derived tumour creators EPO-GmbH will bring drug candidate selection to a “new level” for US drug researchers.
12-Jan-2012 By Gareth Macdonald
Cyprotex says bigger preclinical CROs are stuck in toxicity testing ‘time warp’, citing drug industry demand for innovative cellular methods as key to its second half performance.
12-Jan-2012 By Nick Taylor
Charles River’s CEO has reiterated the importance of integrating its research models and preclinical units but refused to discuss takeover reports.
12-Jan-2012
Custom antibody manufacturer Cambridge Research Biochemicals (CRB) has expanded its range of labelling dyes through a new agreement with supplier Life Technologies.
10-Jan-2012 By Nick Taylor
Charles River is reportedly considering selling the business, with private equity and rival companies believed to be possible buyers.
Bioligands bought by investors and UK's Bridge BioResearch
10-Jan-2012
Preclinical molecular biology services firm BioLigands has changed ownership.
EU preclinical CROs partner on profiling & discovery services
09-Jan-2012
European CROs Dualsystems Biotech and NiKem Research have partnered to offer drug profiling and discovery services.
05-Jan-2012 By Nick Taylor
Biopharm companies have inked a raft of contract service deals at the start of 2012 in efforts to push compounds into the clinic.
22-Dec-2011 By Nick Taylor
BASi is optimistic Gilead Sciences’ $11bn acquisition of Pharmasset, the CRO’s biggest client, will be positive for the business.
21-Dec-2011 By Nick Taylor
BASi posted its first full year net profit since 2007, despite a fourth quarter loss, and is seeking to expand its services with acquisitions.
Frontage and Janssen develop preclinical metformin testing method
update
19-Dec-2011 By By Natalie Morrison
Frontage Laboratories has teamed up with Janssen Pharmaceuticals to develop a chromatographic preclinical testing method they say could finally solve metformin development issues.
15-Dec-2011 By Natalie Morrison
AIT Bioscience says its new alliance with Perfinity Biosciences will provide protein analysis in 10 minutes, rather than the 48 hours that is standard across the industry.
15-Dec-2011 By Nick Taylor
Charles River wants to buy drug discovery assets to meet interest in strategic outsourcing of non-regulated efficacy testing.
14-Dec-2011 By Gareth Macdonald
Prestwick Chemical and Pharma Plexus Holland have set up a lead optimisation services collaboration intended to meet industry demand for larger candidate selection projects.
CRL’s preclinical arm will struggle, but RMS and strategic deals hold hope for 2012
13-Dec-2011 By Gareth Macdonald
Charles River Laboratories’ (CRL) preclinical division will continue to struggle in 2012 but the recent uptick in strategic partnership activity is a ray of hope according to a leading analyst.
Canadian VC fund sets up discovery chemistry services CRO
12-Dec-2011 By Gareth Macdonald
AmorChem Financial says its new contract research organisation (CRO) - set up to support in-house development - has spin-out potential.
Lonza wins preclinical testing contract for ‘virus supressing factor’
08-Dec-2011 By Gareth Macdonald
Lonza will supply preclinical immunogenicity testing services for a candidate protein antiviral being worked on by South Korean biotech ImmuneMed.
UK government make health data available in bid to boost R&D sector
01-Dec-2011 By Natalie Morrison
Pharma companies and contract research organisations will soon be able to view important UK health data.
Biotechs fear being overlooked by the big CROs; Covance
28-Nov-2011 By Nick Taylor
Fear of getting “lost in the shuffle” makes some biotechs nervous about outsourcing to big CROs, a Covance VP said.
Forming CRO spin-outs can help big pharma; research
24-Nov-2011 By Nick Taylor
Spinning-out assets to form a CRO can help large biopharm commercialise knowledge and focus on core activities, research found.
ShangPharma opening facility dedicated to major customer
22-Nov-2011 By Nick Taylor
ShangPharma is opening a 100,000 sq ft facility dedicated to serving a big customer as it continues to strengthen ties to top clients.
ICH approves revision to preclinical genotoxicity testing guidelines
16-Nov-2011
The ICH has approved a revision to its genotoxicity testing and data interpretation guidelines that it says will improve risk assessment and reduce the number of animals used during preclinical development.
Tranzyme and B-MS extend their drug discovery collaboration
08-Nov-2011
Tranzyme Pharma has extended its drug discovery collaboration with Bristol-Myers Squibb.
Establishing R&D bonds is wave of the future, says Lilly boss
08-Nov-2011 By Natalie Morrison
Drug researchers must integrate development programs more to drive the industry into the 21st century, says Eli Lilly CEO John Lechleiter.
Cyprotex invests to meet demand for cell-based preclinical tox
08-Nov-2011 By Gareth Macdonald
Cyprotex says increasing demand for cell-based preclinical toxicology services in North America prompted facility expansion plan.
Gentronix partners to add cell health assays for early research
02-Nov-2011 By Nick Taylor
Gentronix has added cell health assays through a partnership with BioQuanta to detect toxicity earlier in development.
Analyst calls for Covance to cut early development capacity
24-Oct-2011 By Nick Taylor
Covance should cut early development capacity as demand is returning slowly and will likely fail to reach prior levels, an analyst said.
New Hamner - PBM venture says its toxicity testing could save billions in drug discovery
19-Oct-2011 By Natalie Morrison
The Hamner Institutes for Health Sciences and private equity firm PBM Capital Group (PBM) have thrashed out a venture for toxicity testing which they say could save the drug discovery industry billions.
Pharma R&D efficiency demands driving discovery services sector, says BASi CEO
17-Oct-2011 By Gareth Macdonald
US CRO Bioanaltyical Systems (BASi) says Big Pharma demand for R&D efficiency is driving growth of outsourced drug discovery services sector.
